WB result of FGF21 Recombinant Rabbit mAb
Primary antibody: FGF21 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: 293T whole cell lysate 20 µg
Lane 2: PC-3 whole cell lysate 20 µg
Lane 3: U-2 OS whole cell lysate 20 µg
Lane 4: K562 whole cell lysate 20 µg
Lane 5: HepG2 whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 22 kDa
Observed MW: 22 kDa
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | FGF21 |
| Synonyms | Fibroblast growth factor 21; FGF-21 |
| Immunogen | Synthetic Peptide |
| Location | Secreted |
| Accession | Q9NSA1 |
| Clone Number | S-2567-21 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu, Ms, Rt |
| Positive Sample | 293T, PC-3, U-2 OS, K562, HepG2, C2C12, mouse spleen, rat spleen |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000-1:2000 | Hu, Ms, Rt |
Background
Fibroblast growth factor 21 (FGF21) is a 181-amino-acid, liver-derived atypical member of the FGF family that functions as a fasting-induced hormone—binding β-Klotho–FGFR1c complexes in adipose tissue and brain—to orchestrate systemic glucose, lipid and energy homeostasis by promoting insulin sensitivity, enhancing white-fat browning and thermogenesis, suppressing hepatic gluconeogenesis and lipogenesis, and centrally modulating appetite and circadian behavior; its circulating levels surge in response to nutrient deprivation, protein restriction, high-sucrose or high-fat diets, cold exposure, mitochondrial stress and alcoholic or non-alcoholic liver injury, while pharmacologic administration of engineered FGF21 analogs has shown potent, dose-dependent reductions in body weight, plasma triglycerides, LDL-cholesterol and fasting glucose in obese, diabetic and NASH patients, making FGF21 a promising therapeutic target for metabolic disease.
Picture
Picture
Western Blot
WB result of FGF21 Recombinant Rabbit mAb
Primary antibody: FGF21 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: C2C12 whole cell lysate 20 µg
Lane 2: mouse spleen lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 22 kDa
Observed MW: 22 kDa
WB result of FGF21 Recombinant Rabbit mAb
Primary antibody: FGF21 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: rat spleen lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 22 kDa
Observed MW: 22 kDa
